Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serotonin toxicity in a CYP2D6 poor metabolizer, initially diagnosed as a drug-resistant major depression.

The American journal of psychiatry - 1 Aug 2014

Gressier Florence, Ellul Pierre, Dutech Céline, Ait Tayeb Abd El Kader, Monfort Joel, Corruble Emmanuelle, Becquemont Laurent, Hardy Patrick, Verstuyft Céline

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclohexanols
Share to Cytochrome P-450 CYP2D6
Share to Delayed-Action Preparations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Selective Serotonin Reuptake Inhibitors

Share to Venlafaxine Hydrochloride

Source

Identifiers

PMID: 25082493
DOI: 10.1176/appi.ajp.2014.13101377

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serotonin toxicity in a CYP2D6 poor metabolizer, initially diagnosed as a drug-resistant major depression.PMID 25082493Read ↗

Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping.Semantic proximity Read ↗

Serotonin syndrome following drug-drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient.Semantic proximity Read ↗

Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype.Semantic proximity Read ↗

eComment: Serotonin syndrome: pharmacogenomics and treatment.Semantic proximity Read ↗

Pharmacogenetics and the pharmacological management of depression.Semantic proximity Read ↗

A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment.Semantic proximity Read ↗

Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.Semantic proximity Read ↗

Novel CYP2D6 and CYP2C19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetineSemantic proximity Read ↗

Association between CYP2D6 genotype and treatment effectiveness and safety in 99 hospitalized patients with major depressive disorder a retrospective cohort study CYP2D6 genotype and antidepressant response.Semantic proximity Read ↗

Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group.Semantic proximity Read ↗

A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication.Semantic proximity Read ↗

Drug interactions--friend or foe?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.